Stoke Therapeutics Inc
NASDAQ:STOK
Stoke Therapeutics Inc
NASDAQ:STOK
Price:
14.86 USD
-2.3%
Market Closed
Updated:
Jun 9, 2024
Stoke Therapeutics Inc
Cash from Operating Activities
|
Stoke Therapeutics Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Stoke Therapeutics Inc
NASDAQ:STOK
|
Cash from Operating Activities
-$84.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
24%
|
See Also
What is Stoke Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-84.3m
USD
-84.3m
USD
Based on the financial report for Mar 31, 2024, Stoke Therapeutics Inc's Cash from Operating Activities amounts to -84.3m USD.
What is Stoke Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-40%
-40%
Over the last year, the Cash from Operating Activities growth was 2%. The average annual Cash from Operating Activities growth rates for Stoke Therapeutics Inc have been -18% over the past three years , -40% over the past five years .
You don't have any saved screeners yet
